Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278866 | 0.84 | CA2 (0.37) | KDM4ECA2CHKANPC1LMNA | |
| SCHEMBL17816462 | 0.83 | CA2 (0.40) | KDM4ECA2CHKAUHRF1THRB | |
| SCHEMBL12859621 | 0.81 | AAK1 (0.35) | CA2CHKAUHRF1THRBALDH1A1 | |
| SCHEMBL31691999 | 0.81 | CA2 (0.39) | CA2CHKAUHRF1THRBAAK1 | |
| SCHEMBL11981574 | 0.81 | KMT2A (0.31) | CA2CHKAUHRF1THRB | |
| SCHEMBL20320546 | 0.81 | KDM4E (0.36) | KDM4ECA2CHKAUHRF1THRB | |
| SCHEMBL17816467 | 0.81 | CA2 (0.39) | CA2CHKAUHRF1THRBAAK1 | |
| SCHEMBL7704073 | 0.78 | CA2 (0.56) | KDM4ECA2CHKAUHRF1LMNA | |
| SCHEMBL30849517 | 0.78 | — | — | |
| SCHEMBL17226913 | 0.78 | KDM4E (0.31) | KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-07-04 | — | — | US | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-11690850-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690850-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230193265-A1 | CUG REPEAT SEQUENCE BINDING AGENT | OSAKA UNIVERSITY (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-7598245-B2 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | KDM4E 3667/4885CA2 3052/4885CHKA 71/4885 |
| US-11690850-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | KDM4E 3689/4885CA2 4643/4885CHKA 629/4885 |
| US-11771684-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, DEGS1, SMPD1 | KDM4E 4599/4885CA2 2611/4885CHKA 825/4885 |
| US-20230193265-A1 | CUG REPEAT SEQUENCE BINDING AGENT | CNBP, ZFR, HNRNPUL2 | KDM4E 2563/4885CA2 3831/4885CHKA 4320/4885 |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | ITGB6, ITGA5, ITGAV | KDM4E 3196/4885CA2 3868/4885CHKA 2972/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | KDM4E 3667/4885CA2 3052/4885CHKA 71/4885 |
| US-20080096901-A1 | Aminotriazole compounds useful as inhibitors of protein kinases | MAP3K20, MAP3K5, MAP3K1 | KDM4E 1081/4885CA2 1812/4885CHKA 558/4885 |
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | KDM4E 2026/4885CA2 1481/4885CHKA 259/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | KDM4E 3817/4885CA2 3043/4885CHKA 1877/4885 |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDM4E 3792/4885CA2 3325/4885CHKA 1645/4885 |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | KDM4E 3817/4885CA2 3043/4885CHKA 1877/4885 |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | KDM4E 3817/4885CA2 3043/4885CHKA 1877/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | KDM4E 3041/4885CA2 3958/4885CHKA 299/4885 |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDM4E 3792/4885CA2 3325/4885CHKA 1645/4885 |
| US-20110117073-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, PACSIN2, MAP3K9 | KDM4E 1628/4885CA2 1948/4885CHKA 153/4885 |
| US-20240217963-A1 | RECEPTOR-INTERACTING PROTEIN 1 INHIBITORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK4 | KDM4E 4076/4885CA2 4520/4885CHKA 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.